Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodality Therapy vs Standard Systemic Therapy in HER2+ De Novo Oligometastatic Breast Cancer
NCT07578116Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2027
- Primary completion
- May 2032
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (3 cohorts), sponsored by SWOG Cancer Research Network. Primary endpoints: Overall Survival (Cohort A) at 10 years, Progression-Free Survival (Observational Cohort B) at 5 years and 1 more. Planned start Mar 2027; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07578116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578116.